Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial

Published 2014 View Full Article

Authors

Keywords

Journal

LANCET ONCOLOGY

Volume 15, Issue 13, Pages 1493-1502

Publisher

Elsevier BV

Online

2014-10-30

DOI

10.1016/s1470-2045(14)70475-9

Ask authors/readers for more resources

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

LANCET ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Discover Peeref hubs

Publish scientific posters with Peeref